Anteris Technologies Looks Bullish If DurAVR's PARADIGM Delivers

Anteris Technologies is developing DurAVR, a differentiated biomimetic TAVR device with encouraging early clinical data in ...

Paradigm Health Launches SPIRE to Accelerate Late-Phase Clinical Evidence Generation

Paradigm Health today announced SPIRE -- Scalable Platform for Integrated Research & Evidence -- a new model for post-approval and late-stage clinical studies designed to help sponsors generate ...
Clinical Trials Arena on MSN

Paradigm Health debuts post-marketing study tool for routine care integration

SPIRE is designed to allow more routine care providers in community and rural settings to participate in post-marketing ...
Morningstar

New Peer-Reviewed Research Demonstrates Effectiveness of Paradigm Health Study Conduct Products

COLUMBUS, Ohio and NEW YORK, April 8, 2026 /PRNewswire/ -- New peer-reviewed research demonstrates the feasibility and effectiveness of Paradigm Health's EHR-integrated eSource platform to support ...
Seeking Alpha

FDA Approves Anteris’s DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)

The PARADIGM Trial is a prospective randomized controlled trial (RCT) which will evaluate the safety and effectiveness of the DurAVR ® THV compared to commercially available transcatheter aortic valve ...
Morningstar

JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity

The Journal of the American Medical Association (JAMA Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase 2b trial in ALS, including slower ...
Stockhead on MSN

Health check: Paradigm holders go for extra fries in super-sized placement

Paradigm Biopharmaceuticals upsizes placement by 75% Chimeric trial results offer early-stage hope to leukemia patients All ...
Business Insider

FDA Approves Anteris’s DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)

PARADIGM: A P rospective rA ndomized tR ial A ssessing the safety and effectiveness of the D urAVR ® bI omimetic valve designed for physioloG ic flow compared to CoM mercial TAVR devices MINNEAPOLIS ...